Company intelligence

NVCT

Nuvectis Pharma, Inc. · NASDAQ · Healthcare

Price$25.89+8.46% · +$2.02

Market cap687.03MEquity value

P / E-19.8Trailing ratio

Volume276.41KLatest session

Market data

NVCT price chart

TradingView

Related signals

1 min delayed

Browse public NVCT signals with their source context and measured market impact. Open any signal for its permanent analysis page.

NVCTJun 22, 2026+24.38% since signal

Nuvectis expands pipeline with exclusive outside-China rights to two Haisco drugs

Nuvectis Pharma said it licensed exclusive rights outside China to two experimental drugs from Haisco, broadening its pipeline into complement-mediated diseases and cancer. The deal provides a strategic expansion for NVCT’s portfolio, with potential milestone and royalty opportunities if programs advance, though no terms were disclosed.

View signal analysis

NVCTNov 14, 2024-10.49% since signal

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nuvectis Pharma's NVCT stock fell 43.20% after Phase 1b study results. In interim data, efficacy was seen in 11 out of 12 patients. Thrombocytopenia issues were common but improved with a new dosing schedule. FDA granted Fast Track and Orphan Drug Designations for NXP800. Upcoming data expected in Q2 2025 from additional patient cohort.

View signal analysis

Research